Search Results

You are looking at 1 - 10 of 74 items for :

  • "hyperplasia" x
Clear All
Full access

Therese B. Bevers, Benjamin O. Anderson, Ermelinda Bonaccio, Sandra Buys, Mary B. Daly, Peter J. Dempsey, William B. Farrar, Irving Fleming, Judy E. Garber, Randall E. Harris, Alexandra S. Heerdt, Mark Helvie, John G. Huff, Nazanin Khakpour, Seema A. Khan, Helen Krontiras, Gary Lyman, Elizabeth Rafferty, Sara Shaw, Mary Lou Smith, Theodore N. Tsangaris, Cheryl Williams and Thomas Yankeelov

) or atypical hyperplasia; and 6) women with a prior history of breast cancer. Women at Normal Risk: For women between 20 and 39 years of age, a CBE every 1 to 3 years is recommended, with breast awareness encouraged. For women aged 40 years and

Full access

Amy Ly, Jill C. Ono, Kevin S. Hughes, Martha B. Pitman and Ronald Balassanian

findings. Benign Table 1. Patient Demographics diagnoses included fibrous tissue/scar, fibrocystic change, mastitis, keratin cyst, bacterial infection, pseudoangiomatous stromal hyperplasia, fat necrosis, lipoma, fibroadenoma, hamartoma

Full access

Parijatham S. Thomas

benign disease. 1 However, not all benign breast biopsies are equal, and certain lesions confer an increased risk for breast cancer. Specifically, lesions with atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS) have been shown to be

Full access

Benjamin O. Anderson, Kristine E. Calhoun and Eric L. Rosen

mucin-secreting carcinoma . J Clin Pathol 1975 ; 28 : 711 – 716 . 22. Rosen P . Lobular carcinoma and hyperplasia . In: Rosen P, ed. Breast Pathology . Philadelphia : Lippincott-Raven ; 1997 : 507 – 544 . 23. Acs G Lawton

Full access

Damon Reed, Ragini Kudchadkar, Jonathan S. Zager, Vernon K. Sondak and Jane L. Messina

. (C) Spitzoid melanoma from 17-year-old patient. Although resembling a Spitz nevus by virtue of epidermal hyperplasia and epithelioid cell component, there is marked atypical and sheet-like growth of dermal component, with severe pleomorphism in the

Full access

Sanjeev Kumar Gupta, Nitin Jain, Guilin Tang, Andrew Futreal, Sa A. Wang, Joseph D. Khoury, Richard K. Yang, Hong Fang, Keyur P. Patel, Rajyalakshmi Luthra, Mark Routbort, Bedia A. Barkoh, Wei Chen, Xizeng Mao, Jianhua Zhang, L. Jeffrey Medeiros, Carlos E. Bueso-Ramos and Sanam Loghavi

–11 × 10 9 /L), and a normal platelet count (152 × 10 9 /L; reference, 150–450 × 10 9 /L). The differential leukocyte count showed monocytosis (47%) and eosinophilia (15%). BM examination showed hypercellular (∼95%) BM with myelomonocytic hyperplasia and

Full access

Arvind Bambhroliya, Mariana Chavez-MacGregor and Abenaa M. Brewster

higher self-perceived risk of developing breast cancer is positively associated with acceptance of risk reduction medications, 35 , 38 and uptake has been shown to be significantly higher among women with a history of atypical hyperplasia or LCIS 17 , 20

Full access

Tanner M. Johanns, Cole J. Ferguson, Patrick M. Grierson, Sonika Dahiya and George Ansstas

, and predominantly epithelioid morphology ( Figure 1A ). Although necrosis was not convincingly present, large areas of hemorrhage, focal endothelial hyperplasia ( Figure 1B ) and vascular thrombosis were present. The tumor was widely infiltrative

Full access

Therese B. Bevers, Deborah K. Armstrong, Banu Arun, Robert W. Carlson, Kenneth H. Cowan, Mary B. Daly, Irvin Fleming, Judy E. Garber, Mary Gemignani, William J. Gradishar, Helen Krontiras, Swati Kulkarni, Christine Laronga, Loretta Loftus, Deborah J. MacDonald, Martin C. Mahoney, Sofia D. Merajver, Ingrid Meszoely, Lisa Newman, Elizabeth Pritchard, Victoria Seewaldt, Rena V. Sellin, Charles L. Shapiro and John H. Ward

Hodgkin disease], hormone replacement therapy [HRT], alcohol consumption); and other factors (e.g., number of breast biopsies, atypical hyperplasia or lobular carcinoma in situ [LCIS], breast density, body mass index). Estimating breast cancer risk for

Full access

Therese B. Bevers

identify women for whom risk reduction therapy should be seriously considered. So who are these women? Women for whom the benefits of risk reduction therapy almost always outweigh the harms are those with atypical hyperplasia (AH), both ductal and lobular